DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

UNH·UnitedHealth Group Incorporated

$.
-. (-.%)
After Hours
High
$433.99
Open
$431.67
Market Cap
385.62B
52W High
$434.30
Low
$423.65
P. Close
$424.58
P/E
32.02
52W Low
$234.60
Fwd P/E
20.24
DailyIQ Est.
$437.58
Technical Score (1D)
82
BUY
News Sentiment
68
BULLISH
UnitedHealth Group surged to a 52‑week high of $434.30 after RBC lifted its price target to $463, citing robust managed‑care trends that bode well for the upcoming Q2 earnings season. The rally is also fueled by growing optimism around AI‑enabled healthcare services, which could lift demand for UnitedHealth’s technology‑driven benefit offerings. RBC’s upgrade underscores the company’s ongoing cost‑control initiatives and a strong earnings trajectory, suggesting that the stock may continue to benefit from a favorable operating environment in the near term. UnitedHealthcare’s launch of a Lifestyle Spending Account offers employers a flexible benefit that may increase member engagement and broaden the company’s employer‑sponsored product suite. The new spending account could also influence utilization patterns and cost structures, potentially affecting the company’s margin profile over the next few weeks. The company’s recent rebound from a sharp decline tied to the tragic death of its former CEO has restored investor confidence, but the volatility that accompanied that episode may still weigh on short‑term sentiment. As the Q2 earnings season approaches, analysts will be closely monitoring revenue growth, margin expansion, and the effectiveness of the new spending account in driving member usage. Traders should also keep an eye on any regulatory developments that could impact benefit design or cost‑control measures, as these could alter the company’s operating dynamics.
Earnings Summary
UnitedHealth Group is a diversified healthcare enterprise that delivers a broad spectrum of services through its four primary segments—UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx—positioning it as a leading player in the U.S. healthcare plans sector. In the most recent quarter, the company posted Q4 2024 revenue of $100.81 billion and EPS of $6.81, narrowly beating the $6.74 estimate, while Q1 2025 revenue rose to $109.58 billion and EPS of $7.20 fell short of the $7.29 forecast; Q2 2025 revenue climbed to $111.62 billion with EPS of $4.08 versus a $4.45 estimate, and Q3 2025 revenue reached $113.16 billion with EPS of $2.92 beating the $2.81 target; Q4 2025 revenue dipped slightly to $113.22 billion and EPS of $2.11 missed the $2.12 estimate, but Q1 2026 revenue rebounded to $111.72 billion and EPS of $7.23 exceeded the $6.60 forecast, giving the firm a 3‑of‑6 quarter beat record and a steady upward trajectory in revenue growth that has accelerated from 8.8 % YoY in Q1 2025 to 12.3 % YoY in Q4 2025 before a modest 1.7 % decline in Q1 2026. Historically, UnitedHealth has maintained consistent year‑over‑year revenue expansion while its EPS has shown volatility, with recent beats in Q4 2024, Q3 2025, and Q1 2026 offset by misses in the intervening quarters, underscoring a pattern of robust top‑line growth amid earnings swings. Recent news highlights include RBC’s 52‑week high and price‑target lift driven by AI‑enabled services, the launch of a Lifestyle Spending Account that could reshape member utilization and margins, and a leadership reset following a CEO return and audit completion that has restored investor confidence; regulators remain watchful of a DOJ probe into Medicare Advantage operations. Investors should watch for the company’s guidance on revenue growth, margin expansion, and the operational impact of the new spending account, as well well as any updates on the DOJ probe and AI‑related revenue, which will be key to assessing UnitedHealth’s near‑term earnings momentum.

EPS

EstBeatMiss
$1.33$3.02$4.70$6.39$8.07Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.85 - -
Q1'26$6.60$7.23+9.5%
Q4'25$2.12$2.11-0.6%
Q3'25$2.81$2.92+4.0%
Q2'25$4.45$4.08-8.2%
Q1'25$7.29$7.20-1.3%

Revenue

EstBeatMiss
$108.8B$110.5B$112.3B$114.0B$115.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$110.8B - -
Q1'26$109.7B$111.7B+1.9%
Q4'25$115.0B$113.2B-1.5%
Q3'25 - $113.2B -
Q2'25 - $111.6B -
Q1'25 - $109.6B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

UNH Stock Snapshot

UNH is currently trading at $424.50, giving UnitedHealth Group Incorporated a market cap of 385.62B and a P/E ratio of 32.0. Today's range spans $423.65–$433.99, with shares opening at $431.67 and moving down $0.08 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 68/100.

Over the past year UNH has traded between $234.60 and $434.30 - the current price is +80.9% off the 52-week low and -2.3% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $420.46 (range $287.00–$492.00), implying downside of -1.0%.

Growth-oriented Healthcare investors looking for technical confirmation find it in UNH: BUY signal, 82/100 score, bullish sentiment at 68/100, price $424.50 (near 52-week highs). The current P/E ratio stands at 32.0. The 385.62B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $234.60–$434.30.

The combination of a BUY signal (82/100) and bullish news sentiment (68/100) puts UNH on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 385.62B in Healthcare market cap without immediately moving the stock. At $424.50 (near 52-week highs in the $234.60–$434.30 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.